Key Highlights:
- The CPHI Annual Industry Survey reveals that the pharma sector is on the cusp of a major shift, with approvals for complex molecules expected to outpace those for small molecules for the first time.
- The report predicts that Bio and Tides will be the fastest growing modality for CDMOs over the next five years.
- Last year's report showed ADCs surprisingly finished last achieving just 15% of the vote, while small molecules remained consistent with 35%.
Ahead of CPHI Milan – the world’s largest pharma event, held at Fiera Milano [8-10 October] – new insights from the CPHI Annual Industry Survey* reveal that the pharma sector is on the cusp of a major shift, with approvals for complex molecules expected to outpace those for small molecules for the first time. In 2023, of the 55 new drug approvals, nine were for tides (five peptides and four oligonucleotides), with a further 17 biologics.